Oppenheimer initiated coverage on Ligand Pharma with a new price target
$LGND
Biotechnology: Pharmaceutical Preparations
Health Care
Oppenheimer initiated coverage of Ligand Pharma with a rating of Outperform and set a new price target of $135.00
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 3/11/2026 | $244.00 | Buy | BofA Securities |
| 12/9/2025 | $270.00 | Buy | Citigroup |
| 4/10/2025 | $143.00 | Buy | Stifel |
| 10/3/2024 | $135.00 | Outperform | Oppenheimer |
| 7/30/2024 | $130.00 | Outperform | RBC Capital Mkts |
| 2/22/2022 | $180.00 → $130.00 | Buy | Benchmark |
| 2/18/2022 | $185.00 → $165.00 | Overweight | Barclays |
| 9/22/2021 | $174.00 → $180.00 | Overweight | Barclays |
BofA Securities initiated coverage of Ligand Pharma with a rating of Buy and set a new price target of $244.00
Citigroup initiated coverage of Ligand Pharma with a rating of Buy and set a new price target of $270.00
Stifel initiated coverage of Ligand Pharma with a rating of Buy and set a new price target of $143.00
4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
8-K - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
8-K - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
DEFA14A - LIGAND PHARMACEUTICALS INC (0000886163) (Filer)
4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
4 - LIGAND PHARMACEUTICALS INC (0000886163) (Issuer)
Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset potential dilution to Ligand’s common stock upon conversion of the notes JUPITER, Fla., June 23, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) ("Ligand") announced today the pricing of $625.0 million aggregate principal amount of 0.0% convertible senior notes due 2031 (the "notes") in a private placement (the "offering") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "Sec
Opportunistic capital raise with proceeds used to enhance financial flexibility A portion of the proceeds to be used to purchase call spreads and to fund concurrent share repurchase intended to offset potential dilution to Ligand’s common stock upon conversion of the notes JUPITER, Fla., June 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) ("Ligand") announced today its intention to offer $550.0 million aggregate principal amount of convertible senior notes due 2031 (the "notes") in a private placement (the "offering") to persons reasonably believed to be qualified institutional buyers pursuant to Rule 144A under the Securities Act of 1933, as amended (the "
JUPITER, Fla., June 10, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will host an Investor Day in New York City on Tuesday, December 8, 2026 at 10:30 a.m. Eastern time at the Harvard Club. The event will include presentations from Ligand's senior management team highlighting the company's strategy, recent investment activity, royalty portfolio, and long-term financial outlook. A live webcast of the event will be accessible through Ligand's Investor Relations website at investor.ligand.com. A detailed agenda, including dial-in information, will be provided closer to the event. About Ligand Ligand is a leading royalty aggregator, partne
SC 13G/A - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)
SC 13G - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)
SC 13G/A - LIGAND PHARMACEUTICALS INC (0000886163) (Subject)
The combined company plans to launch ZELSUVMI™ for the treatment of molluscum contagiosum infections in July 2025 Concurrent with the closing of the merger, the combined company closed on a $50.1 million equity private placement Combined company will operate under the name "Pelthos Therapeutics Inc." and will trade on the NYSE American exchange under the ticker symbol "PTHS" starting on July 2, 2025 DURHAM, N.C., July 02, 2025 (GLOBE NEWSWIRE) -- Pelthos Therapeutics Inc., a biopharmaceutical company committed to commercializing innovative therapeutic products for high unmet patient needs, today announced the closing of the previously announced merger agreement pursuant to which CHRO Me
WAYNE, Pa., Oct. 17, 2024 (GLOBE NEWSWIRE) -- Palvella Therapeutics, Inc., a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapies to treat patients suffering from serious, rare genetic skin diseases for which there are no FDA-approved therapies, today announced the appointment of Matthew E. Korenberg as Chief Financial Officer, effective immediately. Mr. Korenberg is a seasoned operational and financial leader with more than 27 years of senior executive experience in biotech companies and healthcare investment banking. Throughout his career, he has focused on capital raising, partnering and licensing deals, acquisitions, as well as overseeing p
Leading Antibody Discovery Technologies Enable Development of Innovative Therapeutics Regular-way Trading of OABI Begins November 2, 2022 on Nasdaq OmniAb, Inc. (NASDAQ:OABI) today announced the completion of the expected tax-free spin-off from Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) and the subsequent business combination with Avista Public Acquisition Corp. II (NASDAQ:AHPA), resulting in OmniAb becoming an independent publicly traded company. Based on actual redemptions and estimated transaction expenses, OmniAb expects to have approximately $95 million in cash at closing. OmniAb will begin regular-way trading November 2, 2022 on Nasdaq under the stock ticker symbol "OABI." "
First quarter performance driven by strong year-over-year royalty revenue growth of 56% Reaffirms Previously Raised 2026 Full-Year Financial Guidance Reflecting Anticipated Partial-Year Contribution from Pending XOMA Royalty Acquisition Conference call begins at 8:30 a.m. Eastern Time today JUPITER, Fla., May 07, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today reported financial results for the three months ended March 31, 2026, and provided an operating forecast and business update. Ligand management will host a conference call and webcast today at 8:30 a.m. Eastern Time to discuss the results and answer questions. "The first few months of 2026 have al
Transaction expands Ligand's royalty portfolio to more than 200 assets and adds seven new commercial products Bolsters and diversifies Ligand's long-term compounding growth, adding a complementary portfolio across development stages, therapeutic areas, and modalities to broaden patient access and improve lives Acquisition is expected to be immediately accretive to Ligand adjusted EPS; Ligand increases 2026 adjusted EPS guidance to $8.50-$9.501 and expects the transaction to be accretive by $1.50 per share to adjusted EPS in 20272 Ligand to hold investor call at 8:00 a.m. ET today JUPITER, Fla. and EMERYVILLE, Calif., April 27, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporate
JUPITER, Fla., April 22, 2026 (GLOBE NEWSWIRE) -- Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) today announced that it will report first quarter 2026 financial results on Thursday, May 7, 2026. The company will hold a conference call beginning at 8:30 a.m. Eastern time to discuss the results and provide a general business update. Conference Call and Webcast Information Date: Thursday, May 7, 2026 Time: 8:30 a.m. Eastern time Conference Call: United States (Local): +1 (585) 542-9983 United States (Toll-Free): +1 (833) 461-5787 International: Global Dial-in NumbersMeeting ID: 304603090 Webcast: Live and replay webcasts of the call are available here. About LigandLigand is a